Compare Roblox Corp (RBLX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs TG Therapeutics Inc — how do they compare? Roblox Corp trades at $49.83 (market cap $37.59B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Roblox Corp is far larger — about 4.6× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Roblox Corp nearer its low. Which is the better fit depends on your goals.
| RBLX | TGTX | |
|---|---|---|
Market Cap | $37.59B | $8.26B |
Sector | Media | Health |
52-Week High | $141.56 | $59.06 |
52-Week Low | $41.30 | $26.39 |
Enterprise Value | $36.18B | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox trades at $52.50, up 1.59% with neutral technical signals. The company shows strong revenue growth reaching $4.89B in 2025 but continues to report significant losses with a -20.69% net margin. Analyst consensus is bullish with a $59.62 price target, though multiple class action lawsuits filed in July 2026 create near-term uncertainty. Operating cash flow improved to $1.8B, supporting ongoing platform investments.
Roblox presents a growth investment case with expanding user engagement and AI innovation, but profitability challenges and legal risks require careful monitoring. The stock offers 13.6% upside to consensus target, though high P/S ratio of 7.03 and negative ROE of -295.16% highlight valuation concerns amid persistent losses.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
